Dane Leone
Stock Analyst at Raymond James
(1.62)
# 3,062
Out of 4,789 analysts
88
Total ratings
36.76%
Success rate
-6.35%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.68 | +487.37% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $6.76 | +565.68% | 2 | Feb 21, 2024 | |
| BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $85.94 | +16.36% | 9 | Dec 22, 2023 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $33.62 | -10.77% | 1 | Nov 16, 2023 | |
| BLUE bluebird bio | Maintains: Outperform | $200 → $260 | $5.25 | +4,852.38% | 6 | Nov 8, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $617.00 | +53.97% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $1.85 | +604.61% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $33.02 | +39.31% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $24.77 | +178.56% | 5 | May 8, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $2.47 | +1,074.09% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $8 | $2.24 | +257.14% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $29 → $14 | $6.54 | +114.07% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $9.69 | +498.56% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $24.10 | +190.46% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.37 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $37.50 | +68.00% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $59.55 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.46 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $48.92 | +32.87% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.86 | - | 5 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $306.92 | -16.92% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $3.37 | +849.55% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $153.25 | - | 2 | Jul 21, 2017 |
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.68
Upside: +487.37%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $6.76
Upside: +565.68%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $85.94
Upside: +16.36%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $33.62
Upside: -10.77%
bluebird bio
Nov 8, 2023
Maintains: Outperform
Price Target: $200 → $260
Current: $5.25
Upside: +4,852.38%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $617.00
Upside: +53.97%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $1.85
Upside: +604.61%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $33.02
Upside: +39.31%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $24.77
Upside: +178.56%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $2.47
Upside: +1,074.09%
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $2.24
Upside: +257.14%
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $6.54
Upside: +114.07%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $9.69
Upside: +498.56%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $24.10
Upside: +190.46%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.37
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $37.50
Upside: +68.00%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $59.55
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.46
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $48.92
Upside: +32.87%
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $7.86
Upside: -
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $306.92
Upside: -16.92%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $3.37
Upside: +849.55%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $153.25
Upside: -